Opus Genetics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share amounts and par value)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $30,321 | $50,501 |
| Accounts receivable | 3,563 | 926 |
| Contract assets and unbilled receivables (Note 10) | 2,209 | 1,407 |
| Prepaids and other current assets | 515 | 1,099 |
| Short-term investments | 2 | 15 |
| Total current assets | 36,610 | 53,948 |
| Property and equipment, net | 252 | — |
| Total assets | $36,862 | $53,948 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,148 | $2,153 |
| Accrued expenses | 8,145 | 1,815 |
| Derivative liability | 2 | 74 |
| Total current liabilities | 11,295 | 4,042 |
| Total liabilities | 11,295 | 4,042 |
| Commitments and contingencies (Note 3 and Note 9) | ||
| Series A preferred stock, par value $0.0001; 14,146 shares and no shares were designated as of December 31, 2024 and 2023, respectively; 14,145.374 and no shares issued and outstanding at December 31, 2024 and 2023, respectively. | 18,843 | — |
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 9,985,854 and 10,000,000 shares authorized as of December 31, 2024 and 2023, respectively; no shares issued and outstanding at December 31, 2024 and 2023. | — | — |
| Common stock, par value $0.0001; 125,000,000 and 75,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 31,574,657 and 23,977,491 shares issued and outstanding at December 31, 2024 and 2023, respectively. | 3 | 2 |
| Additional paid-in capital | 145,719 | 131,370 |
| Accumulated deficit | (138,998) | (81,466) |
| Total stockholders’ equity | 6,724 | 49,906 |
| Total liabilities, series A preferred stock, and stockholders’ equity | $36,862 | $53,948 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.